Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Gains from Investment Securities (2016 - 2025)

Cytokinetics (CYTK) has disclosed Gains from Investment Securities for 14 consecutive years, with $2.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities changed N/A to $2.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.4 million, a N/A change, with the full-year FY2025 number at $2.5 million, up 12889.47% from a year prior.
  • Gains from Investment Securities was $2.5 million for Q4 2025 at Cytokinetics, up from $15630.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $83.2 million in Q3 2021 to a low of -$78.8 million in Q4 2021.
  • A 5-year average of $1.9 million and a median of $274188.5 in 2024 define the central range for Gains from Investment Securities.
  • Biggest YoY gain for Gains from Investment Securities was 28467.62% in 2021; the steepest drop was 14676.55% in 2021.
  • Cytokinetics' Gains from Investment Securities stood at -$78.8 million in 2021, then skyrocketed by 89.01% to -$8.7 million in 2022, then fell by 21.47% to -$10.5 million in 2023, then surged by 100.77% to $80573.0 in 2024, then skyrocketed by 2963.06% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Gains from Investment Securities are $2.5 million (Q4 2025), $15630.0 (Q2 2025), and $467804.0 (Q1 2025).